Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | TRPM5 | Q9NZQ8 | 12/20 | 0.38 |
| ▸ | TRPM4 | Q8TD43 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2581080 | 0.84 | KCNH2 (0.34) | TRPM5TRPM4MEN1ALDH1A1HPGD | |
| SCHEMBL2585459 | 0.80 | HTR2A (0.35) | TRPM5TRPM4 | |
| SCHEMBL29334281 | 0.78 | TRPM5 (0.32) | TRPM5TRPM4 | |
| SCHEMBL2578504 | 0.75 | TRPM5 (0.39) | PTGS2TRPM5TRPM4MEN1ALDH1A1 | |
| SCHEMBL2349484 | 0.73 | TRPM5 (0.32) | TRPM5 | |
| SCHEMBL2344424 | 0.72 | CHRNA7 (0.32) | MEN1ALDH1A1LMNAHPGDKMT2A | |
| SCHEMBL16564923 | 0.72 | PNMT (0.38) | ALDH1A1MAPT | |
| SCHEMBL16553583 | 0.72 | PNMT (0.38) | ALDH1A1MAPT | |
| SCHEMBL3618110 | 0.72 | CHRNA7 (0.32) | MEN1ALDH1A1LMNAHPGDKMT2A | |
| SCHEMBL29337867 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8048878-B2 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-01 | — | — | US | disclosed |
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | PTGS2 1483/4885TRPM5 2497/4885TRPM4 2949/4885 |
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | PTGS2 4180/4885TRPM5 225/4885TRPM4 123/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | PTGS2 1483/4885TRPM5 2497/4885TRPM4 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.